Open Access

[Corrigendum] The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells

  • Authors:
    • Jun Fujiwara
    • Yoshihiro Sowa
    • Mano Horinaka
    • Makoto Koyama
    • Miki Wakada
    • Tsuneharu Miki
    • Toshiyuki Sakai
  • View Affiliations

  • Published online on: November 25, 2015     https://doi.org/10.3892/ijo.2015.3265
  • Pages: 854-854
  • Copyright: © Fujiwara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Article

View Figures

Related Articles

Journal Cover

February 2016
Volume 48 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Fujiwara, J., Sowa, Y., Horinaka, M., Koyama, M., Wakada, M., Miki, T., & Sakai, T. (2016). [Corrigendum] The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells. International Journal of Oncology, 48, 854-854. https://doi.org/10.3892/ijo.2015.3265
MLA
Fujiwara, J., Sowa, Y., Horinaka, M., Koyama, M., Wakada, M., Miki, T., Sakai, T."[Corrigendum] The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells". International Journal of Oncology 48.2 (2016): 854-854.
Chicago
Fujiwara, J., Sowa, Y., Horinaka, M., Koyama, M., Wakada, M., Miki, T., Sakai, T."[Corrigendum] The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells". International Journal of Oncology 48, no. 2 (2016): 854-854. https://doi.org/10.3892/ijo.2015.3265